StockNews.AI
RCKT
StockNews.AI
15 days

DEADLINE NEXT WEEK: Rocket Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Securities Class Action Lawsuit

1. Rocket Pharmaceuticals faces class action lawsuit for misleading trial information. 2. Clinical hold placed on RP-A501 after patient death during study. 3. Lawsuit alleges nondisclosure of serious trial protocol amendments. 4. Potential investors urged to participate in identification of lead plaintiff.

7m saved
Insight
Article

FAQ

Why Very Bearish?

Historical precedents demonstrate class action lawsuits often depress stock prices significantly, as seen in other biotech companies. Recent news of a patient death and regulatory hold makes RCKT's situation particularly precarious.

How important is it?

The lawsuit's potential ramifications on RCKT's stock and investor confidence are significant, making it critical for potential investors to monitor closely.

Why Short Term?

The immediate impact of the lawsuit and clinical hold will likely affect RCKT's stock quickly, similar to previous cases of biotech firms experiencing rapid sell-offs post-litigations.

Related Companies

VRTXCRSPCGTX
, /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that the Rocket Pharmaceuticals class action lawsuit – captioned Ho v. Rocket Pharmaceuticals, Inc., No. 25-cv-10049, and pending in the District of New Jersey – seeks to represent purchasers or acquirers of Rocket Pharmaceuticals, Inc. (NASDAQ: RCKT) securities and charges Rocket Pharmaceuticals and one of Rocket Pharmaceuticals' top executives with violations of the Securities Exchange Act of 1934. A subsequently filed case is captioned Yankov v. Rocket Pharmaceuticals, Inc., No. 25-cv-13532 (D.N.J.). If you suffered substantial losses and wish to serve as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit, please provide your information here: https://www.rgrdlaw.com/cases-rocket-pharmaceuticals-inc-class-action-lawsuit-rckt.html You can also contact attorneys J.C. Sanchez or Jennifer N. Caringal of Robbins Geller by calling 800/449-4900 or via e-mail at [email protected]. Lead plaintiff motions for the Rocket Pharmaceuticals class action lawsuit must be filed with the court no later than Monday, August 11, 2025. CASE ALLEGATIONS: Rocket Pharmaceuticals operates as a late-stage biotechnology company that focuses on developing gene therapies for rare and devastating diseases. The Rocket Pharmaceuticals class action lawsuit alleges that defendants provided investors with material information concerning Rocket Pharmaceuticals' Phase 2 pivotal trial of RP-A501 for the treatment of Danon disease while, at the same time, disseminating materially false and misleading statements and/or concealing material adverse facts concerning the true state of RP-A501's safety and clinical trial protocol; notably, that Rocket Pharmaceuticals knew Serious Adverse Events, including death of participants enrolled in the study, were a risk. In particular, Rocket Pharmaceuticals amended the trial's protocol to introduce a novel immunomodulatory agent to the pretreatment regimen without providing this critical update to shareholders, according to the complaint. The Rocket Pharmaceuticals class action lawsuit further alleges that on May 27, 2025, Rocket Pharmaceuticals announced that the U.S. Food and Drug Administration placed a clinical hold on the RP-A501 Phase 2 pivotal study after at least one patient suffered a Serious Adverse Event, ultimately, death, while enrolled in the study following a substantive amendment to the protocol that Rocket Pharmaceuticals failed to disclose to investors at the time management made the revision. On this news, the price of Rocket Pharmaceuticals stock fell, according to the complaint. THE LEAD PLAINTIFF PROCESS: The Private Securities Litigation Reform Act of 1995 permits any investor who purchased or acquired Rocket Pharmaceuticals securities during the Class Period to seek appointment as lead plaintiff in the Rocket Pharmaceuticals class action lawsuit. A lead plaintiff is generally the movant with the greatest financial interest in the relief sought by the putative class who is also typical and adequate of the putative class. A lead plaintiff acts on behalf of all other class members in directing the Rocket Pharmaceuticals class action lawsuit. The lead plaintiff can select a law firm of its choice to litigate the Rocket Pharmaceuticals class action lawsuit. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff of the Rocket Pharmaceuticals class action lawsuit. ABOUT ROBBINS GELLER: Robbins Geller Rudman & Dowd LLP is one of the world's leading law firms representing investors in securities fraud and shareholder litigation. Our Firm has been ranked #1 in the ISS Securities Class Action Services rankings for four out of the last five years for securing the most monetary relief for investors. In 2024, we recovered over $2.5 billion for investors in securities-related class action cases – more than the next five law firms combined, according to ISS. With 200 lawyers in 10 offices, Robbins Geller is one of the largest plaintiffs' firms in the world, and the Firm's attorneys have obtained many of the largest securities class action recoveries in history, including the largest ever – $7.2 billion – in In re Enron Corp. Sec. Litig. Please visit the following page for more information: https://www.rgrdlaw.com/services-litigation-securities-fraud.html Past results do not guarantee future outcomes. Services may be performed by attorneys in any of our offices.  Contact:            Robbins Geller Rudman & Dowd LLP            J.C. Sanchez, Jennifer N. Caringal            655 W. Broadway, Suite 1900, San Diego, CA 92101            800-449-4900            [email protected]  SOURCE Robbins Geller Rudman & Dowd LLP WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In

Related News